63 results
8-K
EX-99.1
ANNX
Annexon Inc
13 May 24
Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones
4:05pm
.
Research and development (R&D) expenses: R&D expenses were $21.0 million for the quarter ended March 31, 2024, reflecting the advancement of the Company’s … )
Three Months Ended
March 31,
Operating expenses:
Research and development (1)
General and administrative (1)
Total operating expenses
Loss from
424B5
ANNX
Annexon Inc
5 Apr 24
Prospectus supplement for primary offering
4:07pm
from this offering for working capital and general corporate purposes, including research and development expenses, general and administrative … plans;
our expectations with regard to the results of our clinical studies, preclinical studies and research and development programs, including
8-K
EX-99.1
7gyo9ycq4gd
26 Mar 24
Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones
4:05pm
8-K
EX-99.1
snkxyk3pvsnic1hyj7
4 Mar 24
Regulation FD Disclosure
5:25pm
8-K
EX-1.1
ama5pn 37oy8so5jg
21 Dec 23
Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock
4:09pm
424B5
nsvclkj6a9z
21 Dec 23
Prospectus supplement for primary offering
4:05pm
8-K
EX-99.1
ixapnl0ky4863g440n
13 Nov 23
Annexon Reports Significant Progress with its Priority Programs and Third Quarter 2023 Financial Results
4:10pm
8-K
EX-99.1
luza1zxgxa4oat7m
7 Aug 23
Annexon Highlights Recent Pipeline and Business Progress and Reports Second Quarter 2023 Financial Results
4:12pm
8-K
EX-99.1
13llbks5px1nkx22
8 May 23
Annexon Reports First Quarter 2023 Financial Results and Highlights Recent Pipeline Progress
4:11pm
424B3
qns355
16 Nov 22
Prospectus supplement
4:26pm
S-3
0q3ls0b xss28b7k2
4 Nov 22
Shelf registration
4:47pm